Effect of Sugarcane Juice on Liver Patients

August 14, 2024 updated by: Naeem Mujahid, Pir Mehr Ali Shah Arid Agriculture University
This study aims to investigate the potential benefits of sugarcane juice on liver health in patients who are suffering from liver-related conditions. We hypothesize that regular consumption of sugarcane juice may improve liver function and alleviate symptoms in patients with liver disease. Patients participating in this study will consume a specified amount of sugarcane juice daily for 90 days, and their liver health will be monitored to assess any improvements. This study could help identify a natural, accessible treatment option to support liver health in patients with liver disease, potentially improving their quality of life.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This randomized controlled trial (RCT) is designed to evaluate the impact of sugarcane juice on liver health in patients diagnosed with liver-related conditions, including cirrhosis, hepatitis, and fatty liver disease. The study aims to assess whether sugarcane juice, administered in varying dosages, has a therapeutic effect on liver enzyme levels and overall liver function.

Study Design

This is an interventional study using a randomized controlled trial (RCT) design. Participants will be randomly assigned to one of four groups: three treatment groups and one control group. The treatment groups will receive daily doses of sugarcane juice at 170mL, 230mL, and 300mL, respectively, along with their prescribed medicine, for a duration of three months. The control group will receive no sugarcane juice but will continue their prescribed medication regimen.

Intervention Details

Control Group: Receives no sugarcane juice, only prescribed medication. Group 1: Receives 170mL of sugarcane juice daily along with prescribed medication.

Group 2: Receives 230mL of sugarcane juice daily along with prescribed medication.

Group 3: Receives 300mL of sugarcane juice daily along with prescribed medication.

Duration of the Study

The study will span three months, during which participants' liver health will be monitored at regular intervals.

Outcome Measures

Primary Outcome Measures:

Levels of liver enzymes: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Total Bilirubin.

Secondary Outcome Measures:

Changes in liver-related symptoms, including jaundice, abdominal pain, fatigue, and nausea.

Sample Size

The study will enroll a total of 400 participants. The participants will be divided into four groups:

Control Group: 100 participants Group 1: 100 participants Group 2: 100 participants Group 3: 100 participants

Inclusion and Exclusion Criteria

Inclusion Criteria:

Patients diagnosed with liver disease, including but not limited to cirrhosis, hepatitis, or fatty liver disease.

Age group 20-60 years. Symptoms criteria based on liver disease include jaundice, abdominal pain, fatigue, nausea, and elevated liver enzymes (ALT, AST) as per standard diagnostic criteria.

Exclusion Criteria:

Patients younger than 20 years or older than 60 years. Patients with a history of other chronic conditions that may interfere with liver function, such as chronic kidney disease or heart failure.

Patients who have undergone liver transplantation. Patients currently participating in another clinical trial related to liver disease.

Pregnant or breastfeeding women.

Statistical Analysis Plan

The data will be analyzed using SPSS (version 27). A Two-Way ANOVA will be used to compare the effects of different dosages of sugarcane juice on liver enzyme levels across the treatment groups and control group. Post hoc analysis will be conducted using Tukey's Honest Significant Difference (HSD) test to identify specific group differences.

Quality Assurance Measures

Data Validation: Rigorous input checks, automated testing, and manual reviews will be implemented to ensure data accuracy.

Site Monitoring: Real-time monitoring tools will be employed to track site performance and swiftly identify any data issues.

Auditing: Regular audits will be performed to ensure compliance with the study protocol and to maintain the integrity of the data.

Handling Missing Data

Data Imputation: Both simple and advanced methods will be employed to impute missing data, ensuring the robustness of the dataset.

Data Cleansing: Consistency checks and outlier detection methods will be implemented to correct data errors.

User Feedback: Tools will be provided to allow users to report and correct missing or inconsistent data promptly.

Study Type

Interventional

Enrollment (Actual)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Punjab
      • Rawalpindi, Punjab, Pakistan, 43600
        • Asif Ahmad

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Patients diagnosed with liver disease, Age group 20 to 60years Symptoms criteria based on liver disease include jaundice, abdominal pain, fatigue, nausea, and elevated liver enzymes (ALT, AST) as per standard diagnostic criteria.

Exclusion Criteria:

Patients younger than 20 years or older than 60 years. Pregnant or breastfeeding women Patients who have undergone liver transplantation. Patients with a history of other chronic conditions that may interfere with liver function, such as chronic kidney disease or heart failure.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Group
There are 100 participants in this arm and will only consume their prescribed medicines.
Experimental: Treatment 1
There are 100 participants in this arm who will consume 170mL of fresh sugarcane juice and take their prescribed medicines.
Fresh sugarcane juice in different doses will be given to liver patients for 90 days
Experimental: Treatment 2
There are 100 participants in this arm who will consume 230mL of fresh sugarcane juice and take their prescribed medicines.
Fresh sugarcane juice in different doses will be given to liver patients for 90 days
Experimental: Treatment 3
There are 100 participants in this arm who will consume 300mL of fresh sugarcane juice and take their prescribed medicines.
Fresh sugarcane juice in different doses will be given to liver patients for 90 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Liver Health Status
Time Frame: ["1 Month" at study commencement (Phase 1)]
Liver health status will assessed through liver function tests including, ALT, AST, ALP, and Total Bilirubin in Phase 1.
["1 Month" at study commencement (Phase 1)]
LIver Health Status
Time Frame: [Termination of Phase 2(intervention period), "3 Month"]
Liver health status will assessed through liver function tests including, ALT, AST, ALP, and Total Bilirubin in Phase 2 after completion of three month intervention
[Termination of Phase 2(intervention period), "3 Month"]
LIver Health Status
Time Frame: [Termination of Phase 3 (Washout period), "1 Month"]
Liver health status will assessed through liver function tests including, ALT, AST, ALP, and Total Bilirubin in Phase 3 which is wash-out time
[Termination of Phase 3 (Washout period), "1 Month"]

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dietary Pattern Analysis
Time Frame: [Through studyy compeletion, an avaerage of 9 month]
Dietary patterns will be analyzed using a Food Frequency Questionnaire (FFQ) to evaluate the patients' intake of various food groups. This will include an assessment of the frequency, portion sizes, and overall dietary diversity. The aim is to correlate dietary habits with the study's primary outcomes.
[Through studyy compeletion, an avaerage of 9 month]
Dietary Pattern Assessment
Time Frame: [Through studyy compeletion, an avaerage of 9 month]
A Food Frequency Questionnaire (FFQ) will be administered to assess the dietary patterns of the patients. This questionnaire will capture the frequency, portion size, and types of food consumed over the study period. The collected data will be used to analyze the relationship between dietary patterns and the primary outcomes of the study.
[Through studyy compeletion, an avaerage of 9 month]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 10, 2023

Primary Completion (Actual)

February 10, 2024

Study Completion (Actual)

March 10, 2024

Study Registration Dates

First Submitted

August 11, 2024

First Submitted That Met QC Criteria

August 14, 2024

First Posted (Actual)

August 19, 2024

Study Record Updates

Last Update Posted (Actual)

August 19, 2024

Last Update Submitted That Met QC Criteria

August 14, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AAURwI

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver; Disease, Inflammatory

Clinical Trials on Fresh Sugarcane juice

Subscribe